Leap Therapeutics, Inc. - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi LPTX

Leap Therapeutics, Inc. (LPTX) is developing cancer immunotherapy through strategic partnerships to improve patient survival rates. The EBITDA_Co trend clearly demonstrates the current financial standing, where the metric value stands at . The business relies on grants as there are no sales. High clinical trial costs create a liquidity deficit, forcing the company to constantly raise external capital.
Leap Therapeutics Inc - rincian analitis lan metrik utama (LPTX)

The market assesses the potential of Leap Therapeutics, Inc. (LPTX) through the lens of intellectual property for DKN-01 antibodies, which solidify the company's dominance in the immuno-oncology segment. By analyzing the annual EBITDA, an investor sees the net cash balance from operating activities excluding depreciation and taxes, allowing for an objective assessment of current business efficiency and the stability of its financial foundation.